x

WHO Lists Ninth COVID-19 Vaccine For Emergency Use

The World Health Organization (WHO) on Friday issued an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus.

The vaccine, named CovovaxTM, is produced by the Serum Institute of India under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.

WHO’s EUL procedure assesses the quality, safety, and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

READ ALSO: Again, Nigeria’s Daily COVID-19 Infections Exceed 1,000

“Even with new variants emerging, vaccines remain one of the most effective tools to protect people against serious illness and death from SARS-COV-2,” said Dr. Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products. ‘This listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10% of their populations, while 98 countries have not reached 40%.”

CovovaxTM was assessed under the WHO EUL procedure based on the review of data on quality, safety, and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.

The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally.

CovovaxTM is a subunit of the vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). It requires two doses and is stable at 2 to 8 °C refrigerated temperatures. The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.

The originator product produced by Novavax, named NuvaxovidTM, is currently under assessment by the European Medicines Agency (EMA). WHO will complete its own assessment of this vaccine once the EMA has issued its recommendation.

A meeting of WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) this week also reviewed the vaccine. SAGE formulates specific policies and recommendations for vaccines’ use in populations (i.e. recommended age groups, intervals between doses, specific groups such as pregnant and lactating women) and will issue recommendations for NuvaxovidTM/CovovaxTM in the coming days.

The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines, and diagnostics available as rapidly as possible to address the emergency while adhering to stringent criteria of safety, efficacy, and quality.

According to the WHO, the assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.

The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data, as well as substantial additional data on safety, efficacy, quality, and a risk management plan.

These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.

As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine.

The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety, and efficacy for broader availability.

Hot this week

Protest Rocks Kaduna Over Alleged Oil Cartels Sabotaging Local Refining

By Achadu Gabriel, KadunaProtesters under the banner of Partners...

NCoS Officer, CSC Olukemi Ibikunle Wins 2025 United Nations Award

By Achadu Gabriel, KadunaA Chief Superintendent of Corrections (CSC)...

Kogi Government, FG Empower 8,600 Households with Cash Transfer Programme

By Noah Ocheni, LokojaThe Kogi State Government, in partnership...

Amnesty International Urges FG to Cut Political Spending, Prioritize Economic Diversification

By Noah Ocheni, LokojaAmnesty International has called on the...

Residents decry rise in domestic violence after murder of Army Officer in A’ibom

By Ogenyi Ogenyi, UyoResidents of Uyo and other parts...

Manchester United Owners Issue Fresh Statement Amid Renewed Sale Speculation

Manchester United’s ownership saga has taken another twist after...

WCQ 2026: Troost-Ekong Shines as Nigeria Defeat Lesotho 2–1

Nigeria boosted their 2026 World Cup qualification hopes with...

Nigeria’s World Cup Hopes Boosted as CAF Adjusts Qualification Rules

Nigeria’s chances of qualifying for the 2026 FIFA World...

China, Nigeria Deepen Cultural Ties as 2025 Women’s Film Festival Opens in Abuja

The opening ceremony of the 2025 China Women’s Film...

Langtang North Residents Applaud Council Chairman Tyem for One Year of Developmental Achievements

By Israel Adamu, JosResidents of Langtang North Local Government...

JUST IN: ISWAP Launches Deadly Attack on Military Base in Borno, Soldiers Feared Killed

Several soldiers are feared dead while others sustained injuries...

Today’s football match fixtures

Here’s a clean, reader-friendly rewrite of today’s global football...

Related Articles

Popular Categories

spot_imgspot_img